EntryPoint Capital’s Myriad Genetics MYGN Stock Holding History

EntryPoint Capital’s Portfolio MYGN Stock Details MYGN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q3	–	Sell	-38,634	Closed	-$205K	–	803
2025 Q2	$205K	Buy	38,634 +8,480	+28%	+$50.1K	0.1%	476
2025 Q1	$267K	Sell	30,154 -19,732	-40%	-$237K	0.12%	392
2024 Q4	$684K	Buy	+49,886	New	+$920K	0.29%	31
2024 Q1	–	Sell	-2,819	Closed	-$54K	–	1639
2023 Q4	$54K	Buy	+2,819	New	+$48.8K	0.05%	679

Other funds holding MYGN

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

GCM

Glenview Capital Management New York $3.98B AUM 20.52% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Jacobs Levy Equity Management Florham Park, New Jersey $23.8B AUM 25.4% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

EntryPoint Capital's MYGN Position: Q3 2025 in Review

EntryPoint Capital sold out of Myriad Genetics (MYGN) in Q3 2025, closing a stake of 38,634 shares — an estimated $205K sold.

EntryPoint Capital first reported a position in MYGN in Q4 2023 and held it in 4 quarters. The position peaked at $684K in Q4 2024. 221 funds tracked by Wall St. Rank hold MYGN as of Q3 2025.

EntryPoint Capital reported no remaining Myriad Genetics position as of Q3 2025 after selling out during the quarter.
EntryPoint Capital sold 38,634 Myriad Genetics shares in Q3 2025, an estimated $205K.
EntryPoint Capital first reported a position in Myriad Genetics in Q4 2023 and held it in 4 quarters.
EntryPoint Capital's Myriad Genetics position peaked at $684K in Q4 2024.
221 funds tracked by Wall St. Rank held Myriad Genetics as of Q3 2025.

Based on EntryPoint Capital's 13F filing for Q3 2025, filed 13 Nov 2025.